UNSPSC 51171616: Casanthranol

This classification denotes a laxative with the molecular formula C21H22O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3SJ3U7J6V2, chemically known as (10R)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2R,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one but generally known as casanthranol, which bears US NIH Compound Identifier 51371307. European Medicines Agency schedules Casanthranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13254MIG.

As of Q4 2014, CASANTHRANOL remains the US FDA Preferred Term for this commodity. Casanthranol bears US NLM identifiers UMLS ID C0205705 and NCI Concept Code C28907. SMILES: C1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C=C3C2OC4C(C(C(C(O4)CO)O)O)O)CO)O.

UNSPSC 51171616 Casanthranol, a Commodity code, covers pharmaceutical active ingredients and finished drug products procured by state and local health systems, corrections departments, and cooperative purchasing organizations. Recent state and local solicitations under this code reflect demand for drug-testing specimens, generic pharmaceuticals supplied through state wholesaler networks, and direct-to-manufacturer prescription fulfillment programs. The issuing bodies span state health and human services commissions, county corrections departments, and multi-state cooperative purchasing alliances; activity is concentrated among specialized health procurement offices with ongoing volume commitments rather than episodic purchases.

Recent opportunities include Collin County Community Supervision and Corrections Department's RFP 2026-327, posted July 9, 2026 with a due date of July 23, 2026, soliciting offender specimen collection and drug testing services (approximately 25,031 annual tests at an estimated contract value of $600,000 over two years with three optional one-year renewals); the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with proposals due March 26, 2026, covering distribution across state and local government facilities in Minnesota and Oregon through three authorized wholesalers; and the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs. Geographic activity centers on Texas, Minnesota, and the upper Midwest multi-state procurement corridor. The code shows active procurement momentum in corrections-based drug testing and state pharmaceutical benefit management.